Acadia Pharmaceuticals | ACAD - Cost Of Sales


Acadia Pharmaceuticals reported $28.32M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
ALKERMES USD 120.7M 47.44M Jun/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 4.06M 1.18M Jun/2026
Cytokinetics USD 5.59M 5.43M Jun/2026
Eisai JPY 51.09B 926M Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Incyte USD 104.96M 457K Jun/2026
J&J USD 8B 67M Jun/2026
Moderna USD 93M 862M Jun/2026
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Prothena USD 28.94M 11.58M Sep/2025
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026